Qlife Holding AB (QLIFE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qlife Holding AB (QLIFE) has a cash flow conversion efficiency ratio of -2.207x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.20 Million ≈ $-452.42K USD) by net assets (Skr1.91 Million ≈ $205.01K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Qlife Holding AB (QLIFE) total market value for the company's overall valuation and market capitalisation.
Qlife Holding AB - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Qlife Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Qlife Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qlife Holding AB ranked by their cash flow conversion efficiency. See QLIFE debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Advanced Blockchain AG
XETRA:BWQ
|
-0.273x |
|
Intelligent Living Application Group Inc
NASDAQ:ILAG
|
-0.142x |
|
FIRST LITHIUM MINERALS
F:X28
|
-0.160x |
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
-0.181x |
|
Flour Mills C. Sarantopoulos S.A.
AT:KYSA
|
0.118x |
|
Adroit Infotech Limited
NSE:ADROITINFO
|
0.026x |
|
Interoil Exploration and Production ASA
OL:IOX
|
0.009x |
|
Warehouse REIT plc
LSE:WHR
|
0.027x |
Annual Cash Flow Conversion Efficiency for Qlife Holding AB (2019–2025)
The table below shows the annual cash flow conversion efficiency of Qlife Holding AB from 2019 to 2025. View QLIFE stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-7.51 Million ≈ $-807.98K |
Skr-21.49 Million ≈ $-2.31 Million |
2.862x | -89.06% |
| 2024-12-31 | Skr-1.43 Million ≈ $-153.78K |
Skr-37.37 Million ≈ $-4.02 Million |
26.151x | +1346.70% |
| 2023-12-31 | Skr-23.12 Million ≈ $-2.49 Million |
Skr-41.80 Million ≈ $-4.50 Million |
1.808x | +445.18% |
| 2022-12-31 | Skr91.15 Million ≈ $9.81 Million |
Skr-47.73 Million ≈ $-5.14 Million |
-0.524x | -228.02% |
| 2021-12-31 | Skr163.18 Million ≈ $17.56 Million |
Skr-26.05 Million ≈ $-2.80 Million |
-0.160x | +15.05% |
| 2020-12-31 | Skr89.55 Million ≈ $9.64 Million |
Skr-16.83 Million ≈ $-1.81 Million |
-0.188x | -202.62% |
| 2019-12-31 | Skr62.48 Million ≈ $6.72 Million |
Skr-3.88 Million ≈ $-417.54K |
-0.062x | -- |
About Qlife Holding AB
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Qlife Holding AB (publ) was incorporated in 2019 and is based in Gothenburg, Sweden.